The "Global Migraine Drugs Market (By Drugs -
Triptan, CGRP, Acetylcholine Inhibitors/ Neurotoxins & Others; Nations-The US, the UK, Germany, France, Italy, Spain and Japan) - Outlook 2025" report has been added to ResearchAndMarkets.com's offering.
Under the company's four clinical studies, ACHIEVE I, ACHIEVE II, UBR-MD-04 and 3110-105-002, the ubrogepant demonstrated efficacy, safety and tolerability in the acute treatment of migraine among a broad patient population, including those who had an insufficient response to a
triptan or those patients in whom
triptans were contraindicated, as well as in patients who had moderate to severe CV risk profile.
Limitations of the study include the survey's use of nonvalidated questions, the lack of a formal clinical diagnosis of cluster headache, and the grouping of all
triptans, rather than assessing individual
triptan medications, such as sumatriptan subcutaneous, alone.
Of more than 5,800 migraines treated, investigators reported 832 adverse events, of which 298 were reported as application site reactions and 161 were reported as
triptan related adverse events.
(23) A similar result might be found by combining a
triptan known to be effective for a patient and an NSAID other than naproxen.
The observations that
triptan therapy is ineffective after allodynia has developed, and
triptans are fairly well tolerated in migraineurs with autonomic symptoms; and besides, the higher risk of the development of allodynia and the chronification of migraine in this subgroup are quite remarkable.
Even though
triptans are considered the gold standard acute migraine therapy, only 37% of participants in the detailed 30- to 40-minute survey had ever used a
triptan, and just 15.9% of the overall study population were current users.
For example, extra caution should be observed if a patient is taking an SSRI in addition to a 5-HT1B/1D receptor agonist (
triptan) because of the substrate properties of the
triptan, combined with the inhibition properties of the SSRI with cytochrome P450 2D6 (CYP2D6; Abies & Nagubilli, 2010).
LONDON--Frovatriptan may be the
triptan of choice for the acute treatment of menstrual migraine attacks, according to reanalyses of data from double-blind, randomized crossover trials involving the drug.
LONDON--Frovatriptan might be the
triptan of choice for the acute treatment of menstrual migraine attacks, according to reanalyses of data from double-blind, randomized crossover trials involving the drug.
David Dodick, MD, professor of neurology at Mayo Clinic in Phoenix, explained that
triptan medications used to treat migraine patients are designed to constrict blood vessels, which for centuries were believed to cause migraine.